SCHEMBL6552340

SCHEMBL6552340

CC(N[C@@H](CS)C(=O)O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.54
MAPT P10636 1/20 0.54
THRB P10828 1/20 0.54
ALOX15 P16050 1/20 0.54
NFKB1 P19838 1/20 0.54
PTGS2 P35354 1/20 0.54
THPO P40225 1/20 0.54
RECQL P46063 1/20 0.54
BLM P54132 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ACE P12821 2/20 0.53
FOLH1 Q04609 3/20 0.41
MME P08473 5/20 0.38
NAALAD2 Q9Y3Q0 2/20 0.38
ENPEP Q07075 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CPA1 P15085 1/20 0.37
ACE2 Q9BYF1 1/20 0.37
PTGS1 P23219 1/20 0.36
SLC7A11 Q9UPY5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3714795 1.00 KDM4E (0.54) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL25761663 0.84 KDM4E (0.56) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL1058215 0.84 KDM4E (0.56) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL1058214 0.84 KDM4E (0.56) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL28854052 0.84 KDM4E (0.56) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL27624628 0.83 ACE (0.41) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL23552453 0.82 KDM4E (0.54) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL313275 0.82 KDM4E (0.54) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL7259700 0.82 ACE (0.59) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL107698 0.80 KDM4E (0.52) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250367300-A1 Nanomaterial and Methods of Use Thereof UNIVERSITY OF CONNECTICUT (US) 2025-12-04 US disclosed
US-20250302971-A1 Therapeutic Nanomaterials UNIV CONNECTICUT (US) 2025-10-02 US disclosed
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF UNIVERSITY OF CONNECTICUT (US) 2025-10-02 US disclosed
US-20250229081-A1 NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF UNIVERSITY OF CONNECTICUT 2025-07-17 US disclosed
CN-120202010-A Ligand-oligonucleotide conjugates and linkers for use therewith 上海京新生物医药有限公司 2025-06-24 CN disclosed
US-20250084410-A1 INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF Synthorx, Inc. (US) 2025-03-13 US disclosed
US-20250066799-A1 UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE THE SCRIPPS RESEARCH INSTITUTE 2025-02-27 US disclosed
EP-4504732-A2 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF University of Connecticut (US) 2025-02-12 EP disclosed
US-12214043-B2 Therapeutic nanomaterials UNIVERSITY OF CONNECTICUT 2025-02-04 US disclosed
US-12173291-B2 Unnatural base pair compositions and methods of use THE SCRIPPS RESEARCH INSTITUTE (US) 2024-12-24 US disclosed
US-8987414-B2 Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles AILERON THERAPEUTICS, INC. (US) 2015-03-24 US disclosed
US-20150051155-A1 PEPTIDOMIMETIC MACROCYCLES HOFFMANN-LA ROCHE, INC. 2015-02-19 US disclosed
US-8927500-B2 Peptidomimetic macrocycles AILERON THERAPEUTICS, INC. (US) 2015-01-06 US disclosed
US-20130274205-A1 PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. 2013-10-17 US disclosed
US-20130210745-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2013-08-15 US disclosed
US-20130123169-A1 PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. (US) 2013-05-16 US disclosed
EP-1179612-B1 Process for the electrochemical reduction of organic compounds. CONSORTIUM ELEKTROCHEM IND (DE) 2004-02-11 EP disclosed
US-6669828-B2 For the electrochemical reduction of organic compounds Consortium für elektrochemische Industrie GmbH (DE) 2003-12-30 US disclosed
US-20020027083-A1 For the electrochemical reduction of organic compounds CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH 2002-03-07 US disclosed
EP-1179612-A1 Cathode for electrolytic cells Consortium für elektrochemische Industrie GmbH (DE) 2002-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302971-A1 Therapeutic Nanomaterials TIE1, TEKT1, POLRMT KDM4E 2272/4885MAPT 194/4885THRB 2002/4885
US-20250367300-A1 Nanomaterial and Methods of Use Thereof EPCAM, CD47, JAK2 KDM4E 848/4885MAPT 1013/4885THRB 3982/4885
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF JAK2, JAK1, CHMP4B KDM4E 2142/4885MAPT 605/4885THRB 3115/4885
US-12173291-B2 Unnatural base pair compositions and methods of use RNGTT, SPOUT1, NPEPPS KDM4E 4046/4885MAPT 3580/4885THRB 2274/4885
US-20250066799-A1 UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE RNGTT, SPOUT1, NPEPPS KDM4E 4046/4885MAPT 3580/4885THRB 2274/4885
US-20150051155-A1 PEPTIDOMIMETIC MACROCYCLES TP53, MDM2, MDM4 KDM4E 4446/4885MAPT 1649/4885THRB 3138/4885
US-20250084410-A1 INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF RNGTT, TRMT1, OSGEP KDM4E 3826/4885MAPT 3383/4885THRB 1802/4885
US-20130123169-A1 PEPTIDOMIMETIC MACROCYCLES GHRHR, GHSR, GHITM KDM4E 4259/4885MAPT 3661/4885THRB 142/4885
US-12214043-B2 Therapeutic nanomaterials TIE1, TEKT1, POLRMT KDM4E 2272/4885MAPT 194/4885THRB 2002/4885
US-20130210745-A1 TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES IL33, TPR, CDC37 KDM4E 3882/4885MAPT 1935/4885THRB 599/4885
US-20130274205-A1 PEPTIDOMIMETIC MACROCYCLES PROKR1, GLP1R, PROKR2 KDM4E 4798/4885MAPT 2765/4885THRB 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.